SENP1启动子G-四链体鉴定及其作用研究

目的:研究G-四链体(G4)对SUMO特异性蛋白酶1(SUMO-specific proteases 1,SENP1)基因的转录调控作用。方法:克隆不同的SENP1启动子片段构建SENP1启动子报告质粒,通过报告基因检测鉴定SENP1启动子核心转录调控区;分析SENP1启动子核心转录调控区序列,并进行G4形成序列预测;合成G4形成序列寡核苷酸,利用圆二色谱分析检测G4形成序列寡核苷酸的拓扑结构;通过G4配体TMPyP4处理和过表达G4解旋酶G4R1结合报告基因检测和Western blot鉴定启动子G4对SENP1转录表达的调控作用。结果:发现-910～+226区域是SENP1启动子的核心转录调控区,序列富含G/C;生信分析发现SENP1启动子核心区存在G4形成序列;圆二色谱分析证实SENP1启动子G4形成序列能够形成G4结构;报告基因检测和Western blot检测发现启动子G4对SENP1转录表达具有抑制作用。结论:SENP1启动子核心转录调控区存在G4结构并对其转录表达具有抑制作用,为揭示SENP1在生理和病理过程中的作用机制提供新的研究思路和试验线索。     

SENP1启动子G-四链体鉴定及其作用研究

目的:研究G-四链体(G4)对SUMO特异性蛋白酶1(SUMO-specific proteases 1,SENP1)基因的转录调控作用。方法:克隆不同的SENP1启动子片段构建SENP1启动子报告质粒,通过报告基因检测鉴定SENP1启动子核心转录调控区;分析SENP1启动子核心转录调控区序列,并进行G4形成序列预测;合成G4形成序列寡核苷酸,利用圆二色谱分析检测G4形成序列寡核苷酸的拓扑结构;通过G4配体TMPyP4处理和过表达G4解旋酶G4R1结合报告基因检测和Western blot鉴定启动子G4对SENP1转录表达的调控作用。结果:发现-910～+226区域是SENP1启动子的核心转录调控区,序列富含G/C;生信分析发现SENP1启动子核心区存在G4形成序列;圆二色谱分析证实SENP1启动子G4形成序列能够形成G4结构;报告基因检测和Western blot检测发现启动子G4对SENP1转录表达具有抑制作用。结论:SENP1启动子核心转录调控区存在G4结构并对其转录表达具有抑制作用,为揭示SENP1在生理和病理过程中的作用机制提供新的研究思路和试验线索。     

Kruppel样因子4对内毒素所致IL-6基因表达的调控及机制研究

探讨Kruppel样因子4(KLF4)对内毒素所致白介素(IL-6)的基因表达以及释放的影响,并对其调控机制做了初步研究．使用RT-PCR和Western blot检测KLF4 mRNA和蛋白质的表达．采用KLF4过表达的RAW264.7巨噬细胞株或反义寡核苷酸技术抑制内源性KLF4的表达,用RT-PCR和ELISA检测内毒素(LPS)刺激后IL-6 mRNA和蛋白质的表达．采用荧光素酶报告基因检测RAW264.7细胞中KLF4过表达对IL-6基因启动子报告基因转录活性的影响．使用EMSA法检测细胞中KLF4与IL-6基因启动子区KLF4元件的结合．结果表明：LPS可以诱导RAW264.7巨噬细胞KLF4的表达以及IL-6蛋白表达．KLF4过表达明显抑制IL-6的mRNA和蛋白质的表达,而KLF4缺失使这种作用消失．荧光素酶报告基因的结果显示,KLF4可以抑制LPS所致的IL-6基因启动子的转录活性．EMSA显示KLF4不能与IL-6启动子区的KLF4结合元件直接结合．结果表明,LPS可以促进RAW264.7小鼠巨噬细胞KLF4的表达和IL-6的释放．KLF4能抑制LPS诱导的IL-6表达和释放,其机制是抑制IL-6启动子的转录活性,但KLF4的抑制作用不是通过直接与IL-6基因的启动子区相结合而实现的．     

C/EBP β对APP基因的表达调控作用的研究

该研究成功地构建了C/EBP β过表达慢病毒载体,在体外人胚肾细胞(HEK293FT)进行病毒包装并感染小鼠海马神经元细胞(HT22)。通过荧光素酶报告基因实验(luciferase assay)检测C/EBPβ对淀粉样前体蛋白(amyloid precursor protein,APP)启动子活性的影响;通过实时荧光定量PCR(Q-PCR)来检测C/EBPβ对APP和Sp1在转录水平上的表达;通过蛋白免疫印迹分析(Western blot assay)检测C/EBPβ对APP和Sp1蛋白表达的作用。萤火虫荧光素酶分析结果显示,C/EBPβ对APP启动子的表达有正调控作用;Western blot和Q-PCR分析的结果表明,C/EBPβ对APP和Sp1基因的表达有正调控作用。C/EBPβ对APP基因表达的调控作用的机制可能在于C/EBPβ上调了内源性转录因子Sp1的基因表达,而Sp1基因表达的增强直接导致了APP基因表达的上调。     

沙棘hrh-miRn458靶向转录因子WRI1调控油脂合成

转录因子WRI1 (WRINKLED 1)在油脂合成过程中发挥重要调控作用, 其转录和翻译水平调控机理以及下游的靶基因现已基本明确, 但尚未见其转录后调控的报道。为探讨沙棘(Hippophae rhamnoides) hrh-miRn458与转录因子WRI1之间的靶向关系, 并阐明其在果肉和种子发育过程中的表达模式, 通过生物信息学方法预测hrh-miRn458成熟体序列及其与候选靶基因WRI1的结合位点, 采用双荧光素酶报告基因检测和RNA pull down技术相结合的方法验证hrh-miRn458与WRI1基因之间的靶向关系, 并应用qRT-PCR方法分析hrh-miRn458与WRI1在沙棘不同发育期果肉和种子油脂合成过程中的表达变化。结果表明, 生物信息学预测WRI1基因的CDS区第309-327位与hrh-miRn458成熟体序列的15个碱基互补; 荧光检测显示pmirGLO-WRI1-WT+hrh-miRn458 mimics显著抑制荧光素酶活性(P<0.001); RNA pull down实验证实hrh-miRn458与WRI1存在互作关系; 不同发育期果肉和种子中hrh-miRn458的表达量总体呈先下降后上升趋势, 其靶基因WRI1的表达量则呈先上升后降低趋势; 同一时期, 果肉中hrh-miRn458的表达量明显低于种子, 而果肉中的WRI1表达量则明显高于种子。综上, 沙棘hrh-miRn458靶向转录因子WRI1, 且二者在果肉和种子油脂合成过程中存在负调控关系。研究结果为深入理解沙棘种子油脂合成机制及培育高油品种提供了参考依据。     

棉铃虫细胞色素P450基因CYP9A17v2核心启动子区缺失分析

CYP9A17v2的过量表达与棉铃虫Helicoverpa armigera对拟除虫菊酯类杀虫剂的抗性相关。为了研究CYP9A17v2表达调控机制, 对CYP9A17v2核心启动子区域的功能进行了分析;构建了含荧光素酶报告基因和CYP9A17v2启动子不同长度缺失片段(-1 095~+43)的重组质粒, 转染Sf9细胞瞬时表达后用双荧光素酶报告基因检测系统检测启动子活性。功能分析结果表明: 所有的7个缺失片段均具有启动子活性, -197~+43启动子区域的转录活性最高。在CYP9A17v2基因5′-调控区-197~-113区域内可能存在转录增强因子的结合位点, 而在-1 095~-197区域内可能存在转录抑制因子的结合位点。本研究为探索棉铃虫CYP9A17v2过量表达的转录调控机理奠定了重要基础。     

H-NS蛋白对副溶血弧菌hcp1的转录调控

【目的】研究调控子H-NS对副溶血弧菌T6SS1结构蛋白基因hcp1的转录调控机制。【方法】利用Western blot检测Hcp1蛋白在野生株(WT)和hns基因敲除株(Δhns)中表达水平的差异。提取WT和Δhns的总RNA,采用实时定量RT-PCR的方法验证H-NS对hcp1的转录调控关系。进而采用引物延伸实验研究hcp1的转录起始位点,并根据产物的丰度判断H-NS对hcp1的调控关系。PCR扩增hcp1的整个启动子区DNA序列,并纯化His-H-NS蛋白,通过凝胶阻滞实验(EMSA)验证His-H-NS对hcp1启动子区是否具有直接的结合作用。【结果】Western blot和实时定量RT-PCR结果显示H-NS能抑制hcp1的表达;引物延伸结果显示hcp1只有一个转录起始位点T(–62)(翻译起始位点为+1),且其转录活性是H-NS和σ54依赖性的;EMSA实验表明H-NS对hcp1的启动子区具有直接的结合作用。【结论】H-NS能直接结合到hcp1启动子区而抑制其转录表达。     

GATA1通过上调NANOG促进胰腺癌肿瘤干细胞形成

目的:探究GATA1在胰腺癌肿瘤干细胞形成中的功能和作用机制。方法:通过流式细胞术检测GATA1对胰腺癌肿瘤干细胞形成的影响;通过实时荧光定量PCR和Western印迹筛选和验证GATA1下游的干性基因;通过双萤光素酶报告基因实验和染色质免疫共沉淀明确GATA1的调控机制。结果:GATA1过表达细胞株中肿瘤干细胞含量增加;GATA1上调NANOG的mRNA和蛋白表达水平;GATA1可以增强NANOG启动子的活性;GATA1结合在NANOG启动子-527^-524bp处的GATA序列。结论:GATA1可以通过结合在NANOG启动子上激活其转录,促进胰腺癌肿瘤干细胞的形成。     

鸡PPARγ基因转录本3上游开放阅读框转录后的调控作用

过氧化物酶体增殖物激活受体γ (peroxisome proliferator-activated receptor gamma, PPARγ)是脂肪生成的关键调控因子。本实验室前期研究发现,与人和鼠等哺乳动物PPARγ基因的转录本不同,鸡PPARγ基因的多个转录本5′UTR区存在上游开放阅读框(upstream open reading frames, uORFs)。为了揭示该uORF转录后的调控作用,本研究构建了鸡PPARγ基因转录本3 (cPPARγ3)野生型5′UTR报告基因载体psiCHECK2-cPPARγ3- 5′UTR-WT和uORF突变(uATG突变为终止密码子TGA)的5′UTR报告基因载体psiCHECK2-cPPARγ3- 5′UTR-Mut。将这两个报告基因载体分别转染永生化鸡前脂肪细胞(immortalized chicken pre-adipocytes, ICPA)和鸡胚成纤维细胞DF1,检测海肾荧光素酶报告基因hRluc活性及其mRNA表达。荧光素酶报告基因检测结果显示,在ICPA细胞中,psiCHECK2-cPPARγ3-5′UTR-Mut的hRluc报告基因活性极显著高于psiCHECK2- cPPARγ3-5′UTR-WT (P<0.01);在DF1细胞中,psiCHECK2-cPPARγ3-5′UTR-Mut的hRluc报告基因活性高于psiCHECK2-cPPARγ3-5′UTR-WT,但差异不显著(P>0.05)。qRT-PCR检测hRluc基因mRNA表达结果显示,与psiCHECK2-cPPARγ3-5′UTR-WT相比,在ICPA细胞中,psiCHECK2-cPPARγ3-5′UTR-Mut转染细胞的hRluc基因的mRNA表达水平极显著降低(P<0.01);在DF1细胞中,psiCHECK2-cPPARγ3-5′UTR-Mut转染细胞后,hRluc基因的mRNA表达水平也降低,但差异不显著(P>0.05)。为进一步分析该uORF对鸡cPPARγ3的转录后调控作用,本研究又分别构建了野生型cPPARγ3真核表达载体pcDNA3.1-cPPARγ3-WT和uORF突变的cPPARγ3真核表达载体pcDNA3.1-cPPARγ3-Mut。qRT-PCR检测cPPARγ3的mRNA表达水平,结果显示,在这两种细胞中,pcDNA3.1-cPPARγ3-Mut转染细胞的cPPARγ3 mRNA表达水平均显著低于pcDNA3.1-cPPARγ3-WT转染细胞(P<0.05),但Western blot结果显示,pcDNA3.1-cPPARγ3-Mut转染细胞的PPARγ蛋白表达水平极显著高于pcDNA3.1-cPPARγ3-WT转染细胞(P<0.01)。这些研究结果表明,5′UTR区的uORF抑制鸡cPPARγ3的翻译。     

Some novel flavin-nicotinamide biscoenzymes and their reactivities

The present study was undertaken to investigate flavin-nicotinamide reactions and interactions. A series of novel flavin-nicotinamide biscoenzymes have been synthesized by a general three-step procedure. The structures of these compounds were confirmed by nuclear magnetic resonance spectra, absorption spectra and elemental analysis. These compounds consist of short linear hydrocarbon chains interconnecting the N-1 of nicotinamide and the N-10 of the 7,8-dimethyl-isoalloxazine ring. The compounds were reduced with sodium dithionite (Na₂S₂O₄) and the flavin portion was reoxidized with ferricyanide. Re-reduction of the flavin portion by the nicotinamide portion of the molecule was followed anaerobically at 442 nm. When the interconnecting hydrocarbon chain was unsaturated, a second order reaction was observed with a rate equal to that of lumiflavin and 1-propyl-1,4-dihydronicotinamide (NprNicH₂) under the same conditions. When the two halves of the biscoenzymes were connected by saturated three- and four-carbon chains, the expected unimolecular reaction was not observed. Instead, the reduced biscoenzyme, after separation from excess sodium dithionite, was shown to have a strong absorption at 298 nm. This absorption is characteristic of hydration of dihydronicotinamides at the 5,6-double bond.In further studies, the C₃-biscoenzyme exhibited an absorption at 600 nm due to a complex between the reduced flavin and oxidized nicotinamide portions of the molecule. Absorbance at 600 nm increased linearly with the C₃-biscoenzyme concentration, clearly indicating that this is an intramolecular complex. When the C₃-biscoenzyme was at 0°C in 60–75% dimethylformamide buffer solution, no absorption at 600 nm was observed. When excess dithionite was removed, the spectrum under these conditions showed definite peaks at 297 and 357 nm. These respective peaks were attributed to hydrated dihydronicotinamide and dihydronicotinamide species present in the reaction mixture.The reduced flavin was postulated to be a catalyst for the hydration of dihydronicotinamide. This hypothesis was tested by incubating 1-propyl-1,4-dihydronicotinamide alone and with several concentrations of reduced riboflavin under basic anaerobic conditions. The results show that the reduced flavin increases the rate of disappearance of the dihydronicotinamide species and that the product shows an absorption near 298 nm. These results indicate that a reduced form of the flavin nucleus catalyzes the hydration of dihydronicotinamides.     

Identification of 4-acetoxyaminoquinoline from the hydrolysis of 1-acetoxy-4-acetoxyimino-1,4-dihydroquinoline,in vitro and in vivo properties

4-Acetoxyaminoquinoline (Ac-4-HAQ) (1) was identified as a hydrolysis product of 1-acetoxy-4-acetoxyimino-1,4-dihydroquinoline (diAc-4-HAQO). The reaction allowing the obtention of (1) obeys to a reduction mechanism implying the N₁-O cleavage. The carcinogenic properties of (1) observed by Sato et al. (Japan J. Exp. Med., 40 (1970) 475) in mice were studied in rats with the in vivo system we used previously with 4-nitroquinoline-1-oxide (4-NQO) and 4-hydroxyaminoquinoline-1-oxide (4-HAQO). In rats (1) does not covalently bind DNA. It was, therefore, possible to propose an interpretation of the results obtained by Enomoto et al. (Proc. Soc. Exp. Biol. Med., 136 (1971) 1206) who injected diAc-4-HAQO s.c. to mice and rats. Compound 1 could be responsible for the carcinogenic effects observed through the following pathway: (1) should be formed by hydrolysis of diAc-4-HAQO and reactivated by an enzymatic system to N-oxide derivative, the 4-acetoxyaminoquinoline-1-oxide (Ac-4-HAQO), which constitutes an ultimate carcinogen model of 4-NQO.     

The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206

Cap-dependent translation is a potential cancer-related target (oncotarget) due to its critical role in cancer initiation and progression. 4EGI-1, an inhibitor of eIF4E/eIF4G interaction, was discovered by screening chemical libraries of small molecules. 4EGI-1 inhibits cap-dependent translation initiation by impairing the assembly of the eIF4E/eIF4G complex, and therefore is a potential anti-cancer agent. Here, we report that 4EGI-1 also inhibits mTORC1 signaling independent of its inhibitory role on cap-dependent translation initiation. The inhibition of mTORC1 signaling by 4EGI-1 activates Akt due to both abrogation of the negative feedback loops from mTORC1 to PI3K and activation of mTORC2. We further validated that mTORC2 activity is required for 4EGI-1-mediated Akt activation. The activated Akt counteracted the anticancer effects of 4EGI-1. In support of this model, inhibition of Akt potentiates the antitumor activity of 4EGI-1 both in vitro and in a xenograft mouse model in vivo. Our results suggest that a combination of 4EGI-1and Akt inhibitor is a rational approach for the treatment of cancer.     

The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206

Cap-dependent translation is a potential cancer-related target (oncotarget) due to its critical role in cancer initiation and progression. 4EGI-1, an inhibitor of eIF4E/eIF4G interaction, was discovered by screening chemical libraries of small molecules. 4EGI-1 inhibits cap-dependent translation initiation by impairing the assembly of the eIF4E/eIF4G complex, and therefore is a potential anti-cancer agent. Here, we report that 4EGI-1 also inhibits mTORC1 signaling independent of its inhibitory role on cap-dependent translation initiation. The inhibition of mTORC1 signaling by 4EGI-1 activates Akt due to both abrogation of the negative feedback loops from mTORC1 to PI3K and activation of mTORC2. We further validated that mTORC2 activity is required for 4EGI-1-mediated Akt activation. The activated Akt counteracted the anticancer effects of 4EGI-1. In support of this model, inhibition of Akt potentiates the antitumor activity of 4EGI-1 both in vitro and in a xenograft mouse model in vivo. Our results suggest that a combination of 4EGI-1and Akt inhibitor is a rational approach for the treatment of cancer.     

Quinone-enhanced ascorbate reduction of nitric oxide: role of quinone redox potential

The quinones 1,4-naphthoquinone (NQ), methyl-1,4-naphthoquinone (MNQ), trimethyl-1,4-benzoquinone (TMQ) and 2,3-dimethoxy-5-methyl-1,4-benzoquinone (UQ-0) enhance the rate of nitric oxide (NO) reduction by ascorbate in nitrogen-saturated phosphate buffer (pH 7.4). The observed rate constants for this reaction were determined to be 16±2,215±6,290±14 and 462±18 M^-1 s^-1, for MNQ, TMQ, NQ and UQ-0, respectively. These rate constants increase with an increase in quinone one-electron redox potential at neutral pH, E₇¹. Since NO production is enhanced under hypoxia and under certain pathological conditions, the observations obtained in this work are very relevant to such conditions.     

Crystal Structure of Human Myosin 1c—The Motor in GLUT4 Exocytosis: Implications for Ca Regulation and 14-3-3 Binding

Myosin 1c (Myo1c) plays a key role in supporting motile events that underlie cell migration, vesicle trafficking, insulin-stimulated glucose uptake and hearing. Here, we present the crystal structure of the human Myo1c motor in complex with its light chain calmodulin. Our structure reveals tight interactions of the motor domain with calmodulin bound to the first IQ motif in the neck region. Several of the calmodulin residues contributing to this interaction are also involved in Ca^2 + binding. Contact residues in the motor domain are linked to the central β-sheet and the HO helix, suggesting a mechanism for communicating changes in Ca^2 + binding in the neck region to the actin and nucleotide binding regions of the motor domain. The structural context and the chemical environment of Myo1c mutations that are involved in sensorineural hearing loss in humans are described and their impact on motor function is discussed. We show that a construct consisting of the motor domain of Myo1c and the first IQ motif is sufficient to establish a tight interaction with 14-3-3β (K_D = 0.9 μM) and present the model of a double-headed Myo1c–14-3-3 complex. This complex has been implicated in the exocytosis of glucose transporter 4 storage vesicles during insulin-stimulated glucose uptake.     

4E-BP1、4E-BP1-4A 重组慢病毒载体的构建及对胃癌细胞 HGC27生长的影响

目的:构建4E-BP1及其 T37A、T46A、S65A、T70A 突变体4E-BP1-4A 基表达的重组慢病毒载体,研究其对胃癌 HGC27细胞生长的影响.方法:PCR 扩增4E-BP1基及其突变体4E-BP1-4A 基并克隆到 pCDH 载体,构建成 pCDH-4E-BP1、pCDH-4E-BP1-4A,将其与包装载体共转染293T 细胞,包装成 Lenti-4E-BP1及 Lenti-4E-BP1-4A重组慢病毒载体,将此慢病毒感染胃癌 HGC27细胞,Western 印迹鉴定病毒载体介导的4E-BP1、4E-BP1-4A 蛋白的表达,MTT、克隆形成和软琼脂方法研究过量表达4E-BP1、4E-BP1-4A 对胃癌 HGC27细胞生长的影响.结果:包装成 Lenti-4E-BP1及 Lenti-4E-BP1-4A 重组慢病毒载体,并将此慢病毒载体感染胃癌 HGC27细胞;MTT、克隆形成、软琼脂实验表明过量表达4E-BP1可抑制胃癌 HGC27细胞的生长,过量表达4E-BP1-4A 时抑制效果更明显.结论:构建了4E-BP1、4E-BP1-4A 的重组慢病毒表达载体,在胃癌 HGC27细胞中过量表达4E-BP1可抑制细胞生长,过量表达4E-BP1-4A 的抑制效果更明显.     

A benzo[b]thiophene-based selective type 4 S1P receptor agonist

S1P receptors (S1PR1-5) are a group of GPCRs activated by a high affinity binding with S1P that have important roles in the regulation of the immune system. A potent S1PR agonist FTY720 is an immunomodulator used to treat multiple sclerosis and several ‘second generation’ drugs are under clinical development. Subtype-selective agonists have been reported for each S1PR isotype, some of which are used as pharmacological tools for functional studies. Here we report the discovery and initial characterization of compound 5c, a benzo[b]thiophene amino carboxylate which exhibits potent and selective agonist activity for S1PR4. Compound 5c has an EC₅₀ = 200 nM as an agonist in GTPγ³⁵S binding assay for S1PR4 and exhibits no activity against S1PR1,2,3,5. We confirmed its potent activity and decent S1PR subtype selectivity using biochemical and cellular assays.